Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

Johnson & Johnson (JNJ) closed the most recent trading day at $149.23, moving -0.25% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.3%. At the same time ...

Johnson & Johnson (JNJ) stock saw a decline, ending the day at $149.23 which represents a decrease of $-0.37 or -0.25% from the prior close of $149.6. The stock opened at $149.93 and touched a low of ...

and Johnson & Johnson. Rishabh Mishra Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program Bristol Myers Squibb sues HRSA, claiming its rejection of a ...

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $176.92, representing a 20.98% upside. In a report released on December 11, Citi also maintained ...

Shares of Johnson & Johnson JNJ slid 0.27% to $146.24 Thursday, on what proved to be an all-around rough trading session for ...

Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.36 which represents a decrease of $-2.44 or -1.58% from the prior close of $154.8. The stock opened at $154.8 and touched a low of ...

Johnson & Johnson an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of JNJ ...

This was the stock's second consecutive day of losses.

Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its ...

Notably, the $205 average of analysts’ price estimate for ABBV, reflects over 20% upside from its current levels of around $165. While ABBV stock may outperform JNJ stock in the next three years ...